TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* Patient has type I or type II diabetes~* Patient consulting in the department of Metabolic and Endocrine Diseases (Caremeau Hospital) or the department of Nutritional Diseases and Diabetology (Grau de Roi Medical Center) at the Nîmes University Hospital~* Patient has infected osteoarthritis of the foot according to the International Working Group on the Diabetic Foot with a probability \> 50% (score \>= 2).~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant~* The patient is breastfeeding~* Patient has severe sepsis or a stage 4 infection according to the international consensus on the diabetic foot~* Patient has severe renal insufficiency as defined by glomerular filtration rate \< 30ml/min/1.73 m\^2, calculated according to the MDRD equation, and is not undergoing dialysis~* Patient has a contra-indication for an MRI~* pacemaker~* intracranial clips~* metallic inclusions~* severe claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Included patients (Type: EXPERIMENTAL): Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed high-risk or relapsed solid tumors or brain tumors, including:~  * Metastatic or relapsed Ewing's sarcoma~ * Metastatic or relapsed rhabdomyosarcoma~ * Refractory Wilms' tumor~ * Diffuse anaplastic Wilms' tumor~ * Stage III or IV neuroblastoma~ * Recurrent retinoblastoma~ * Metastatic or relapsed germ cell tumors~ * Metastatic or relapsed other soft tissue sarcomas~ * Small cell ovarian sarcoma~ * Metastatic or relapsed primitive neuroectodermal tumors of the bone~ * Recurrent brain tumors~ * Desmoplastic small round cell tumors~ * Recurrent or metastatic chordomas~ * Metastatic or relapsed hepatoblastoma~* Patients receive peripheral blood stem cell transplantation only if in complete remission or in very good partial remission with no disease progression~* Must have radiologic, nuclear image, or histologic verification of relapse~* Age 1 to 45~* Performance status:Karnofsky 70-100%~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 100,000/mm\^3~* Hemoglobin count at least 10 g/dL~* Bilirubin less than 2 times upper limit of normal (ULN)~* SGOT or SGPT less than 2.5 times ULN~* Creatinine less than 2 times ULN~* Creatinine clearance greater than 70 mL/min~* Cardiac shortening fraction greater than 30%~* Cardiac ejection fraction greater than 45%~* At least 1 week since prior hematopoietic growth factor and recovered~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* Recovered from any prior therapy~Exclusion Criteria:~* Osteogenic sarcoma~* Less than 4 months~* Uncontrolled bleeding~* Congestive heart failure~* Uncontrolled hypertension~* Asthma~* Pregnant or nursing~* Uncontrolled metabolic disease~* Active severe infection~* Allergy to aminothiol compounds~* Prior bone marrow transplantation~* Other concurrent investigational agents

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Solid/brain tumor patients (1-18 years) (Type: EXPERIMENTAL): Patients with solid tumor or brain tumor in the 1-18 years old stratum.
- Solid/brain tumor patients (19-45 years) (Type: EXPERIMENTAL): Patients with solid tumor or brain tumor in the 19-45 years old stratum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-80 years of age;~* histological diagnosis of primary central nervous system lymphoma;~* B-cell proliferation verified by positive staining for CD20;~* \>=1 measurable lesion.~Exclusion Criteria:~* prior chemotherapy, other than corticosteroids, \>=6 weeks before and after diagnosis or surgery;~* history of prior cranial irradiation;~* evidence of plurisystemic non-Hodgkin's lymphoma;~* other active malignant disease (other than basal cell or squamous cell cancer of skin,or cancer in situ of cervix;~* uncontrolled active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven epithelial ovarian cancer~* Previously received no more than 4 cycles of neoadjuvant platinum based chemotherapy, followed by debulking surgery~* ECOG PFS \<_ 2~* Adequate haematological (absolute neutrophil count \>_ 1,500/mm3; platelets \>_ 100,000/mm3; hemoglobin \>_ 100g/L); renal (\<_ upper limit of normal) and hepatic function~* Age \>_ 18 years~* Written informed consent and the ability of the patient to co-operate with treatment and follow up~Exclusion Criteria:~* Contraindication to platinum/Paclitaxel chemotherapy: prior anaphylaxis to Carboplatin/Paclitaxel, unresolved or excessive toxicity from neoadjuvant chemotherapy. Patients must not have suffered significant bone marrow suppression during prior treatment. The significance of previous treatment delay and/or dose modification is to be determined by the Principle Investigator on a patient-by-patient basis.~* Serious concomitant medical condition, which in the investigators opinion would not make the patient a good candidate for the clinical trial.~* Patients with a past or concomitant malignancy other than skin cancer (excluding melanoma)~* Patients known to be serologically positive for Hepatitis B, C or HIV~* History of congestive heart failure or unstable angina or those who had a myocardial infarction within the past 6 months. Patients who were not expected to tolerate the hemodynamic effects of the fluid administered as part of the IP protocol.~* Patients who have not received chemotherapy prior to surgery~* Greater than 6 weeks from time of surgery to commencement of IP chemotherapy~* Residual disease greater than 1 cm at time of surgery. Patients whom in the surgeon's opinion are candidates for such surgery may be consented preoperatively to allow intraoperative IP catheter insertion. If however the surgeon is not able to reduce the bulk of disease to less than or equal to 1 cm, patients will be removed from the study and an IP catheter SHOULD NOT be placed.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IP Cisplatin (Type: EXPERIMENTAL): Patients with epithelial ovarian cancer who have undergone optimal debulking surgery receive IP Cisplatin with IV Paclitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Impairments and Obstructive Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female from 18 to 78 years old~* Patients with obstructive sleep apnea syndrome (Apnea/Hypopnea index \> 15)~* ambulatory patients~* patients who have signed the inform consent form~* patients with health insurance~Exclusion Criteria:~* Body Mass Index upper or equal to 30~* cardiovascular pathology except blood pressure hypertension~* known or treated diabetes~* pathologies with consequence on blood pressure regulation~* drugs intakes with consequence on blood pressure regulation~* patient with chronic obstructive pulmonary disease~* atrial fibrillation or more than 10/minute extrasystoles~* bedridden patients or patients with decreased mobility~* patients working at night or with shift work~* patients with carotid stenting or surgery history~* patients unable to sign the inform consent form~* patients already treated by cPAP or dental appliance for OSAS in the last 6 months~* pregnant or suckling female~* patients under supervision or trusteeship~* patients taking part in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of HSV Testing Among Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14 years of age or older~* Pregnant less than 28 weeks at time of enrollment~* No previous HSV serology within the past year~* able to comprehend english~Exclusion Criteria:~* History of genital herpes~* HIV seropositive~* Any contraindication for sexual activity during pregnancy

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): HSV-2 antepartum testing
- 2 (Type: OTHER): Subjects will receive safer-sex counseling during pregnancy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: 36 Versus 42 Hour Time Interval From Ovulation to Intrauterine Insemination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who can be monitored for follicle growth and hormone measurements on the day of ovulation trigger, or one day before.~2. Patients who have no more than 4 follicles of 14 mm or more~3. Patients who have no more than 6 follicles of 10 mm or more~Exclusion Criteria:~1. Patients who cannot give informed consent to language or comprehension barriers~2. Patients who are deemed to be at high risk for high order multiple gestations~3. Patients who cannot be monitored on the day of hCG administration or one day before

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- 36 hours (Type: ACTIVE_COMPARATOR): Intrauterine insemination 36 hours after ovulation induction
- 42 hours (Type: ACTIVE_COMPARATOR): Intrauterine insemination 42 hours after ovulation induction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 0 to \< 9months~* Patients with clinical, radiographic or histologic diagnosis of infantile hemangioma (IH) requiring medical treatment~* IH patients whose parents desire medical treatment for the IH~* Stable cardiac function~Exclusion Criteria:~* IH patients over 9 months of age.~* Hypersensitivity to propranolol~* Untreated heart failure: If the patient has heart failure associated with the hemangioma, propranolol would be initiated after anti-congestive therapy and under observation as an in-patient.~* Atrioventricular (AV) block~* Resting heart \< 2 SD of normal\*(below)~* Resting blood pressure \< 2 SD of normal\*\*(below)~* Wolff-Parkinson-White syndrome (WPW)~* History of unexplained syncope~* Bronchial asthma~* History of impaired renal or liver function~* Diabetes mellitus

- Gender: ALL
- Minimum Age: None
- Maximum Age: 9 Months
- Healthy Volunteers: f

Study Arms:
- Group A: Corticosteroid with Placebo (Type: OTHER): Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
- Group B: Corticosteroid with Propranolol (Type: OTHER): Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers,~* Written consent, AND~* Age 18-65 years old.~Exclusion Criteria:~* Daily medication,~* Alcohol abuse,~* Pregnancy, OR~* Breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tramadol (Type: ACTIVE_COMPARATOR): CYP2D6 metric
- Omeprazole, losartan, caffeine (Type: ACTIVE_COMPARATOR): CYP2C19, CYP2C9 and CYP1A2 metrics
- Tramadol, omeprazole, losartan and caffeine (Type: ACTIVE_COMPARATOR): CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, \>18 years old~* Histological diagnosis of CD20+ Follicular lymphoma by WHO lymphoma criteria.~* FLIPI intermediate or high risk (2-5 risk factors)~* No prior systemic treatment for NHL~* Measurable disease by CT, with at least one lesion \>1.5 cm in one dimension~* Life expectancy of at least 6 months~* ECOG performance status \> = 2~* Patients must have normal organ and marrow function as defined below:~  * ANC \> = 1,500/uL~ * platelets \> = 100,000/uL~ * total bilirubin \< = 1.5 x upper limit of normal~ * AST(SGOT)/ALT(SGPT) \< = 2.5 X upper limit of normal~ * creatinine \< = 1.5 x upper limit of normal~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test~* Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study until at least 12 weeks after the last weekly veltuzumab infusion.~* Primary CNS lymphoma, HIV lymphoma or transformed lymphoma, or presence of symptomatic CNS metastases or carcinomatous meningitis.~* Bulky disease by CT, defined as any single mass \>10 cm in its greatest diameter~* Disease status eligible for potentially curative external beam radiation (stage 1 or contiguous stage 2 at sites appropriate for radiotherapy)~* Bone marrow involvement ≥25%; patients with CLL~* Pleural effusion with positive cytology for lymphoma~* Patients known to be HIV positive or hepatitis B positive~* Corticosteroid use within 2 weeks, unless 20 mg/day or less at stable dose.~* Prior malignancy with less than a 1-year disease-free interval, excluding non-melanoma skin cancers and carcinoma in situ of the cervix.~* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing bone marrow aspiration (unilateral), with lumbar puncture and intrathecal chemotherapy.~* Age 2 to 17 years~* ASA I-III~* Patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in remission or on the day of anticipated remission procedures occurring at the end of remission induction.~* Patients must have three anticipated bone marrow aspirates and lumbar punctures with intrathecal chemotherapy remaining in their treatment~Exclusion Criteria:~* Newly diagnosed patients~* Patients with low platelet count (less than 50000)~* Patients undergoing bone marrow biopsy in addition to bone marrow aspiration~* Age less than 2 years or over 17 years~* ASA IV-V~* Patients taking opioid medication for pre-existent pain for more than 2 weeks at the time of the procedure~* Neurological impairment that would increase susceptibility to opioids (Down's syndrome)~* Clinical contraindications for general anesthesia (large mediastinal mass) or specific use of propofol, Fentanyl, EMLA, L•M•X 4™ or Lidocaine for injection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Fentanyl-1mcg/kg in 3 ml of Normal Saline
- 2 (Type: ACTIVE_COMPARATOR): Fentanyl - 0.5 mcg/kg in 3 ml normal saline
- 3 (Type: PLACEBO_COMPARATOR): normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Single ventricle physiology congenital heart disease status post Fontan palliation~* Undergoing clinically-indicated liver biopsy~* Ability to tolerate 60 minutes in an MRI scanner without sedation~Exclusion Criteria:~* Known contraindication to MR imaging (e.g., implanted non-MRI compatible device)~* Known or suspected pregnancy. Female subjects of child bearing potential will undergo urine pregnancy testing prior to imaging

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Fontan patients (Type: None): Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues